Assessment of combined muscarinic antagonist and fibrinolytic therapy for inhalation injury

Collette Jonkam, Yong Zhu, Sam Jacob, Sebastian Rehberg, Lillian D. Traber, David N. Herndon, Daniel L. Traber, Hal K. Hawkins, Perenlei Enkhbaatar, Robert A. Cox

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


This study tests the hypothesis that muscarinic receptor antagonist therapy with tiotropium bromide (tiotropium; TIO), alone or in combination with tissue plasminogen activator (TPA), can attenuate pulmonary dysfunction in sheep after smoke inhalation and burn injury. The study consisted of four study groups, sham (uninjured), control (injured and untreated), TIO (injured and treated with nebulized TIO), and TIO + TPA (injured and treated with nebulized TIO and TPA). Cardiopulmonary and ventilatory parameters were monitored for 48 hours. After killing the animal, airway obstruction, submucosal gland neutrophilia, parenchyma histopathology, and lung wet to dry weight ratios were measured. PaO2/FiO2 was significantly improved in the TIO group compared with the control group at 48 hours, 301 ± 149 vs 99 ± 33, respectively, P < .05. At 48 hours, peak airway pres- sures in the control, TIO, and TIO + TPA groups were 35 ± 6, 24 ± 7, and 26 ± 10, respectively, with the mean of the TIO group being significantly different from that of the control group, P < .05. A trend of decreased airway obstruction was seen in the treated animals compared with controls; however, the differences were not statistically significant. The TIO and TIO + TPA groups exhibited significant decreases in gland neutrophilia compared with the control group, P < .05. No differences in parenchyma histopathology and lung edema between injured control and treated groups were observed. Nebulization of TIO was effective in improving pulmonary performance and reducing bronchial submucosal gland neutrophilia in sheep after smoke inhalation and burn injury. There was no additive benefit to the inclusion of nebulized TPA with TIO. (J Burn Care Res 2012;33:524-531).

Original languageEnglish (US)
Pages (from-to)524-531
Number of pages8
JournalJournal of Burn Care and Research
Issue number4
StatePublished - Jul 2012

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Assessment of combined muscarinic antagonist and fibrinolytic therapy for inhalation injury'. Together they form a unique fingerprint.

Cite this